Search Results for "RNAi"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

Effect of RNAi Therapeutics Patisiran and Vutrisiran on Orthostatic Hypotension Due to Dysautonomia in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy

RNAi Therapy in ATTRv Amyloidosis with Polyneuropathy (HELIOS-A): Patient-reported Experiences and Preferences

Targeting Glycolate Oxidase for the Treatment of Primary Hyperoxaluria Type 1: Development and Clinical Characterization of Lumasiran, an RNAi Therapeutic

Zilebesiran as Add-On Therapy in Patients with Hypertension Inadequately Controlled with a Standard Antihypertensive Medication: Efficacy and Safety Results from the KARDIA-2 Study

Consistent antihypertensive efficacy of the RNA interference therapeutic zilebesiran: Subgroup results from the KARDIA-1 phase 2 study in patients with hypertension

RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial

ATTRv-PN Expert Opinion Slide Deck

Recommendations from a panel of experts for the diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States.

The Science of RNA interference (RNAi)

This slide deck provides an overview of the science of RNA interference (RNAi), including mechanism of action and delivery platforms.

The Science of RNAi

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.